Factor This Power Engineering
Live Events
DTECH® Events
POWERGEN™
INFOCAST Events
Calendar
Webinars
Podcasts
Factor This
This Week in Cleantech
Factor This Policycast
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
POWERGEN™
INFOCAST Events
Podcasts
Factor This
Factor This Policycast
This Week in Cleantech
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MaxCyte, Inc. - Common Stock
(NQ:
MXCT
)
1.105
-0.035 (-3.07%)
Streaming Delayed Price
Updated: 11:25 AM EDT, Jul 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MaxCyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
August 06, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
MaxCyte Signs Platform License Agreement with Adicet Bio
August 04, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
July 31, 2025
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies
From
MaxCyte, Inc
Via
GlobeNewswire
Earnings Scheduled For May 7, 2025
↗
May 07, 2025
Via
Benzinga
A Look at MaxCyte's Upcoming Earnings Report
↗
May 06, 2025
Via
Benzinga
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
July 09, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
June 11, 2025
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
May 07, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
April 10, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
March 12, 2025
Via
Benzinga
These stocks are moving in today's after hours session
↗
March 11, 2025
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
March 11, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
February 07, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
Earnings Scheduled For March 11, 2025
↗
March 11, 2025
Via
Benzinga
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
January 30, 2025
From
Glancy Prongay & Murray LLP
Via
Business Wire
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
February 12, 2025
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for...
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
January 30, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MarketBeat Week in Review – 01/20 - 01/24
January 25, 2025
Stocks surged higher as investors reacted positively to dovish tariff news; next week will be highlighted by the Federal Reserve meeting and some tech earnings
Via
MarketBeat
Topics
Economy
Government
World Trade
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
January 23, 2025
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.
Via
MarketBeat
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
January 13, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Retirement of Board Member Art Mandell
December 23, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
December 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
November 13, 2024
Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
November 06, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Participate in Two Upcoming Investor Conferences
October 31, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Appoints Cynthia Collins to its Board of Directors
October 15, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
October 11, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
October 10, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
September 16, 2024
Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology
From
MaxCyte, Inc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
